Don P. Le

Array ( [id] => 11850243 [patent_doc_number] => 20170224735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'COMPOSITIONS, METHODS, AND COMPUTER SYSTEMS RELATED TO MAKING AND ADMINISTERING MODIFIED T CELLS' [patent_app_type] => utility [patent_app_number] => 15/498780 [patent_app_country] => US [patent_app_date] => 2017-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 20087 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15498780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16533335 [patent_doc_number] => 10875919 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-29 [patent_title] => Chimeric receptors and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/498004 [patent_app_country] => US [patent_app_date] => 2017-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 14 [patent_no_of_words] => 40546 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15498004 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11828763 [patent_doc_number] => 09725496 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-08-08 [patent_title] => 'Immunoglobulin chimeric monomer-dimer hybrids' [patent_app_type] => utility [patent_app_number] => 15/491742 [patent_app_country] => US [patent_app_date] => 2017-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 40 [patent_no_of_words] => 37113 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15491742 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12030863 [patent_doc_number] => 20170320962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'MONOCLONAL ANTIBODIES AGAINST C-MET' [patent_app_type] => utility [patent_app_number] => 15/491378 [patent_app_country] => US [patent_app_date] => 2017-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 34825 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15491378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12023684 [patent_doc_number] => 20170313782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'MONOCLONAL ANTIBODIES AGAINST C-MET' [patent_app_type] => utility [patent_app_number] => 15/484583 [patent_app_country] => US [patent_app_date] => 2017-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 34818 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15484583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12151550 [patent_doc_number] => 20180022814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS' [patent_app_type] => utility [patent_app_number] => 15/479500 [patent_app_country] => US [patent_app_date] => 2017-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 15222 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15479500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15694437 [patent_doc_number] => 10603380 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-31 [patent_title] => Chimeric antigen and T cell receptors and methods of use [patent_app_type] => utility [patent_app_number] => 15/475681 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 102 [patent_no_of_words] => 33105 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 297 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15475681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14464583 [patent_doc_number] => 20190183931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => CHIMERIC RECEPTORS TO FLT3 AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/090562 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20068 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16090562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11979347 [patent_doc_number] => 20170283500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'CHIMERIC RECEPTORS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/476699 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 29887 [patent_no_of_claims] => 80 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15476699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11756047 [patent_doc_number] => 20170202913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'CTL INDUCER COMPOSITION' [patent_app_type] => utility [patent_app_number] => 15/474165 [patent_app_country] => US [patent_app_date] => 2017-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8746 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15474165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11963630 [patent_doc_number] => 20170267783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'Cytotoxicity-Inducing Therapeutic Agent' [patent_app_type] => utility [patent_app_number] => 15/467654 [patent_app_country] => US [patent_app_date] => 2017-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 53093 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15467654 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13209215 [patent_doc_number] => 10118964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-06 [patent_title] => Construction and application of bispecific antibody HER2xCD3 [patent_app_type] => utility [patent_app_number] => 15/449656 [patent_app_country] => US [patent_app_date] => 2017-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 14 [patent_no_of_words] => 9422 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15449656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185484 [patent_doc_number] => 20180044419 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2018-02-15 [patent_title] => 'COMBINATION THERAPY WITH A HYALURONAN-DEGRADING ENZYME AND AN IMMUNE CHECKPOINT INHIBITOR' [patent_app_type] => utility [patent_app_number] => 15/444151 [patent_app_country] => US [patent_app_date] => 2017-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 113175 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15444151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11690940 [patent_doc_number] => 20170166656 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'ANTI-HER2 ANTIBODY VARIANTS' [patent_app_type] => utility [patent_app_number] => 15/444037 [patent_app_country] => US [patent_app_date] => 2017-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 30918 [patent_no_of_claims] => 74 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15444037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185484 [patent_doc_number] => 20180044419 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2018-02-15 [patent_title] => 'COMBINATION THERAPY WITH A HYALURONAN-DEGRADING ENZYME AND AN IMMUNE CHECKPOINT INHIBITOR' [patent_app_type] => utility [patent_app_number] => 15/444151 [patent_app_country] => US [patent_app_date] => 2017-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 113175 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15444151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16985510 [patent_doc_number] => 11072666 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-27 [patent_title] => Cell injury inducing therapeutic drug for use in cancer therapy [patent_app_type] => utility [patent_app_number] => 16/083975 [patent_app_country] => US [patent_app_date] => 2017-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 69680 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 193 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16083975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11963624 [patent_doc_number] => 20170267776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'RSPO3 Binding Agents and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/439288 [patent_app_country] => US [patent_app_date] => 2017-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 63749 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15439288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11670046 [patent_doc_number] => 20170158766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'Modulation of Activity of Neurotrophins' [patent_app_type] => utility [patent_app_number] => 15/433349 [patent_app_country] => US [patent_app_date] => 2017-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 16073 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15433349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15634453 [patent_doc_number] => 10590205 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-17 [patent_title] => Chimeric antigen receptor compositions [patent_app_type] => utility [patent_app_number] => 15/433939 [patent_app_country] => US [patent_app_date] => 2017-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 26 [patent_no_of_words] => 38267 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15433939 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11689653 [patent_doc_number] => 20170165366 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 15/430998 [patent_app_country] => US [patent_app_date] => 2017-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 50 [patent_no_of_words] => 69338 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15430998 [rel_patent_id] =>[rel_patent_doc_number] =>)